Yiyi Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yiyi Chen has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Catherine Degnin
Oregon Health & Science University, Portland, OR
2 shared publications Cinda Hugos
VA Portland Health Care System Portland OR United States
2 shared publications- Dennis Bourdette
Neurology, Oregon Health & Science University, Portland, USA
2 shared publications - Shearwood McClelland
Departments of Radiation Oncology and Neurological Surgery, University of Oklahoma Stephenson Cancer Center, University of Oklahoma College of Medicine, Oklahoma City, OK
2 shared publications - Solange Bassale
Biostatistics Shared Resources, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
2 shared publications - Timur Mitin
Department of Radiation Medicine, Oregon Health & Science University, Portland, OR
2 shared publications
Latest Publications
- Open Access
- 31 March 2026
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 24 (1) , 79-87
Early Morbidity of Retroperitoneal Lymph Node Dissection in Testicular Cancer Patients: A Retrospective Cohort Study of the National Surgical Quality Improvement Program Database
Purpose: Complications associated with retroperitoneal lymph node dissection (RPLND) have primarily been described from single-center data. These historical single-center studies often lack standardized reporting preventing combined cohort analysis. Therefore, we describe and discuss the complications associated with RPLND from a prospectively maintained, validated, national database.Materials and Methods: The National Surgical Quality Improvement Program (NSQIP) database was queried for 30-day postoperative complications following RPLND for testicular cancer from 2005–2018, which comprised the cohort for analysis. Complications were subcategorized by organ systems and by Clavien-Dindo classification grade (I–II [low], III–V [high]). A subanalysis of large (>5 cm) retroperitoneal masses was evaluated as a surrogate for postchemotherapy RPLND. Associations with patient and perioperative variables were analyzed with logistic regression.Results: A total of 375 patients met inclusion criteria. Seventy-four patients (19.7%) experienced at least one postoperative complication for a total of 125 complications. The median hospital length of stay was 5 (interquartile range, 4–7) days. Hospital readmission occured in 32 patients (8.5%). There were 52 patients (13.9%) who underwent RPLND for large masses, with a 34.6% complication rate. The most common organ system complications included blood transfusions (11.7%), wound dehiscence/infection (4%), and pulmonary (2.3%). The majority of complications were of low Clavien-Dindo classification grade (12% vs. 3.5%). On univariable analysis, smoking, disseminated cancer, steroid use, older age, low albumin, low hematocrit, low platelet counts, and longer operative times were significantly associated with the occurrence of any complication. Smoking, low hematocrit, and longer operative times remained significant on multivariable analysis.Conclusion: In the NSQIP database, complication rates following RPLND are predominantly of low Clavien-Dindo classification grade and are higher than some previously published single-center series. Increased rates were associated with smoking, unfavorable preoperative blood counts, and longer operative times.
- 31 March 2026
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 24 (1) , 79-87
Open AccessEarly Morbidity of Retroperitoneal Lymph Node Dissection in Testicular Cancer Patients: A Retrospective Cohort Study of the National Surgical Quality Improvement Program Database
Purpose: Complications associated with retroperitoneal lymph node dissection (RPLND) have primarily been described from single-center data. These historical single-center studies often lack standardized reporting preventing combined cohort analysis. Therefore, we describe and discuss the complications associated with RPLND from a prospectively maintained, validated, national database.Materials and Methods: The National Surgical Quality Improvement Program (NSQIP) database was queried for 30-day postoperative complications following RPLND for testicular cancer from 2005–2018, which comprised the cohort for analysis. Complications were subcategorized by organ systems and by Clavien-Dindo classification grade (I–II [low], III–V [high]). A subanalysis of large (>5 cm) retroperitoneal masses was evaluated as a surrogate for postchemotherapy RPLND. Associations with patient and perioperative variables were analyzed with logistic regression.Results: A total of 375 patients met inclusion criteria. Seventy-four patients (19.7%) experienced at least one postoperative complication for a total of 125 complications. The median hospital length of stay was 5 (interquartile range, 4–7) days. Hospital readmission occured in 32 patients (8.5%). There were 52 patients (13.9%) who underwent RPLND for large masses, with a 34.6% complication rate. The most common organ system complications included blood transfusions (11.7%), wound dehiscence/infection (4%), and pulmonary (2.3%). The majority of complications were of low Clavien-Dindo classification grade (12% vs. 3.5%). On univariable analysis, smoking, disseminated cancer, steroid use, older age, low albumin, low hematocrit, low platelet counts, and longer operative times were significantly associated with the occurrence of any complication. Smoking, low hematocrit, and longer operative times remained significant on multivariable analysis.Conclusion: In the NSQIP database, complication rates following RPLND are predominantly of low Clavien-Dindo classification grade and are higher than some previously published single-center series. Increased rates were associated with smoking, unfavorable preoperative blood counts, and longer operative times.
- 1 June 2021
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 17 (3) , 406.e1-406.e7
Perceptions of gender equity in pediatric urology
- 1 June 2021
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 17 (3) , 406.e1-406.e7
Perceptions of gender equity in pediatric urology
- Open Access
- 1 January 2021
- Published by Termedia Sp. z.o.o.
- Vol. 26 (4) , 626-634
Impact of hospital volume on mortality for brain metastases treated with radiation
Background: The impact of hospital volume on cancer patient survival has been demonstrated in the surgical literature, but sparsely for patients receiving radiation therapy (RT). This analysis addresses the impact of hospital volume on patients receiving RT for the most common central nervous system tumor: brain metastases. Materials and methods: Analysis was conducted using the National Cancer Database (NCDB) from 2010-2015 for patients with metastatic brain disease from lung cancer, breast cancer, and colorectal cancer requiring RT. Hospital volume was stratified as high-volume (>= 12 brain RT/year), moderate (5-11 RT/year), and low (< 5 RT/year). The effect of hospital volume on overall survival was assessed using a multivariable Cox regression model. Results: A total of 18,841 patients [9479 (50.3%) men, 9362 (49.7%) women; median age 64 years] met the inclusion criteria. 16.7% were treated at high-volume hospitals, 36.5% at moderate-volume, and the remaining 46.8% at low-volume centers. Multivariable analysis revealed that mortality was significantly improved in high-volume centers (HR: 0.95, p = 0.039) compared with low-volume centers after accounting for multiple demographics including age, sex, race, insurance status, income, facility type, Charlson-Deyo score and receipt of palliative care. Conclusion: Hospitals performing 12 or more brain RT procedures per year have significantly improved survival in brain metastases patients receiving radiation as compared to lower volume hospitals. This finding, independent of additional demographics, indicates that the increased experience associated with increased volume may improve survival in this patient population.
- 1 January 2021
- Published by Termedia Sp. z.o.o.
- Vol. 26 (4) , 626-634
Open AccessImpact of hospital volume on mortality for brain metastases treated with radiation
Background: The impact of hospital volume on cancer patient survival has been demonstrated in the surgical literature, but sparsely for patients receiving radiation therapy (RT). This analysis addresses the impact of hospital volume on patients receiving RT for the most common central nervous system tumor: brain metastases. Materials and methods: Analysis was conducted using the National Cancer Database (NCDB) from 2010-2015 for patients with metastatic brain disease from lung cancer, breast cancer, and colorectal cancer requiring RT. Hospital volume was stratified as high-volume (>= 12 brain RT/year), moderate (5-11 RT/year), and low (< 5 RT/year). The effect of hospital volume on overall survival was assessed using a multivariable Cox regression model. Results: A total of 18,841 patients [9479 (50.3%) men, 9362 (49.7%) women; median age 64 years] met the inclusion criteria. 16.7% were treated at high-volume hospitals, 36.5% at moderate-volume, and the remaining 46.8% at low-volume centers. Multivariable analysis revealed that mortality was significantly improved in high-volume centers (HR: 0.95, p = 0.039) compared with low-volume centers after accounting for multiple demographics including age, sex, race, insurance status, income, facility type, Charlson-Deyo score and receipt of palliative care. Conclusion: Hospitals performing 12 or more brain RT procedures per year have significantly improved survival in brain metastases patients receiving radiation as compared to lower volume hospitals. This finding, independent of additional demographics, indicates that the increased experience associated with increased volume may improve survival in this patient population.
- 1 September 2020
- Published by Elsevier in Clinical Lung Cancer
- Vol. 21 (5) , 443-449.e4
Elective Nodal Irradiation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns
- 1 September 2020
- Published by Elsevier in Clinical Lung Cancer
- Vol. 21 (5) , 443-449.e4
Elective Nodal Irradiation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns
- 1 June 2020
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 38 (6) , 604.e1-604.e7
Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma
- 1 June 2020
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 38 (6) , 604.e1-604.e7
Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma
- Open Access
- 1 April 2019
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 45 (2) , 273-287
Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists
Keywords: Prostatic Neoplasms; Dose Hypofractionation; Neoplasm Grading
- 1 April 2019
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 45 (2) , 273-287
Open AccessIs moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists
Keywords: Prostatic Neoplasms; Dose Hypofractionation; Neoplasm Grading
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
A randomized controlled trial of two group programs in multiple sclerosis: Long-term (12-month) follow-up effects on fatigue and self-efficacy (P3.351)
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
A randomized controlled trial of two group programs in multiple sclerosis: Long-term (12-month) follow-up effects on fatigue and self-efficacy (P3.351)
- Open Access
- 1 January 2015
- Published by Wiley in Journal of Immunology Research
- Vol. 2015, 1-11
Growth Modeling of the Maternal Cytokine Milieu throughout Normal Pregnancy: Macrophage-Derived Chemokine Decreases as Inflammation/Counterregulation Increases
Several recent studies have shown differences in the maternal immune milieu at different phases of pregnancy, but most studies have been cross-sectional or of relatively few time points. Levels of 42 cytokines were determined using a multiplex bead-based assay on archived serum from a cohort of pregnant womenat median of 18 time points tested, from the first trimester through to parturition, per woman. Unconditional growth modeling was then used to determine time-dependent changes in levels of these cytokines. Macrophage-derived chemokine (MDC, aka CCL22) decreases as pregnancy progresses. IL-1β, IL-6, IL-8, IL-12p70, IL-13, IL-15, IP-10, and FLT3-ligand increase as a function of gestational weeks, and IFNα2, IL-1ra, IL-3, IL-9, IL-12p40, and soluble CD40 ligand increase as a function of trimester. As pregnancy normally progresses, a maternal shift away from a type 2-biased immune response and toward an inflammatory/counterregulatory response is observed.- 1 January 2015
- Published by Wiley in Journal of Immunology Research
- Vol. 2015, 1-11
Open AccessGrowth Modeling of the Maternal Cytokine Milieu throughout Normal Pregnancy: Macrophage-Derived Chemokine Decreases as Inflammation/Counterregulation Increases
Several recent studies have shown differences in the maternal immune milieu at different phases of pregnancy, but most studies have been cross-sectional or of relatively few time points. Levels of 42 cytokines were determined using a multiplex bead-based assay on archived serum from a cohort of pregnant womenat median of 18 time points tested, from the first trimester through to parturition, per woman. Unconditional growth modeling was then used to determine time-dependent changes in levels of these cytokines. Macrophage-derived chemokine (MDC, aka CCL22) decreases as pregnancy progresses. IL-1β, IL-6, IL-8, IL-12p70, IL-13, IL-15, IP-10, and FLT3-ligand increase as a function of gestational weeks, and IFNα2, IL-1ra, IL-3, IL-9, IL-12p40, and soluble CD40 ligand increase as a function of trimester. As pregnancy normally progresses, a maternal shift away from a type 2-biased immune response and toward an inflammatory/counterregulatory response is observed. - 18 October 2014
- Published by Wiley in Journal of Applied Polymer Science
- Vol. 132 (9)
Preparation and evaluation of nonphosphate terpolymer as scale inhibitor and dispersant for Ca3(PO4)2, BaSO4, and Iron (III) hydroxide scales
The polymeric scale inhibition and dispersion agents (PAYS) were prepared by graft copolymerization of acrylic acid, allylpolyethoxy carboxylate (APEY) and 2‐acrylamido‐2‐methyl‐propanesulfonic acid by using ammonium persulfate as a radical initiator in aqueous solution, among which APEY was synthesized in laboratory. Structure of PAYS was characterized by Fourier transform infrared spectroscopy. Experimental data showed that the terpolymer was a high‐efficient chelate sorbent, and it exhibited excellent ability for calcium orthophosphate, with approximately 96% efficiency at the dosage of 4 mg/L, as well as high efficiency toward barium sulfate scales nearly 80% inhibition. The effectiveness of PAYS depends on the agent concentration, temperature and the ratio of the reactant. The formation of Ca3(PO4)2 and BaSO4 precipitates was characterized by scanning electron microscopy. It appeared that the crystal shape, size, and the morphology of scale changed apparently at the dosage of 4 and 15 mg/L, respectively. In addition, it has good effect on controlling iron (III) scaling. This study was also devoted to the understanding of the action mechanism of these inhibitors in suppressing the crystal nucleus formation and preventing the crystal growth. Based on the contrast experiment of scale formation, the supposing mechanism diagram was also delineated and analyzed in detail. © 2014 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2015, 132, 41546.
- 18 October 2014
- Published by Wiley in Journal of Applied Polymer Science
- Vol. 132 (9)
Preparation and evaluation of nonphosphate terpolymer as scale inhibitor and dispersant for Ca3(PO4)2, BaSO4, and Iron (III) hydroxide scales
The polymeric scale inhibition and dispersion agents (PAYS) were prepared by graft copolymerization of acrylic acid, allylpolyethoxy carboxylate (APEY) and 2‐acrylamido‐2‐methyl‐propanesulfonic acid by using ammonium persulfate as a radical initiator in aqueous solution, among which APEY was synthesized in laboratory. Structure of PAYS was characterized by Fourier transform infrared spectroscopy. Experimental data showed that the terpolymer was a high‐efficient chelate sorbent, and it exhibited excellent ability for calcium orthophosphate, with approximately 96% efficiency at the dosage of 4 mg/L, as well as high efficiency toward barium sulfate scales nearly 80% inhibition. The effectiveness of PAYS depends on the agent concentration, temperature and the ratio of the reactant. The formation of Ca3(PO4)2 and BaSO4 precipitates was characterized by scanning electron microscopy. It appeared that the crystal shape, size, and the morphology of scale changed apparently at the dosage of 4 and 15 mg/L, respectively. In addition, it has good effect on controlling iron (III) scaling. This study was also devoted to the understanding of the action mechanism of these inhibitors in suppressing the crystal nucleus formation and preventing the crystal growth. Based on the contrast experiment of scale formation, the supposing mechanism diagram was also delineated and analyzed in detail. © 2014 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2015, 132, 41546.